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IMPORTANCE Non–vitamin K oral anticoagulants (NOACs) are commonly prescribed with
other medications that share metabolic pathways that may increase major bleeding risk.
OBJECTIVE To assess the association between use of NOACs with and without concurrent
medications and risk of major bleeding in patients with nonvalvular atrial fibrillation.
DESIGN, SETTING, AND PARTICIPANTS Retrospective cohort study using data from the Taiwan
National Health Insurance database and including 91 330 patients with nonvalvular atrial
fibrillation who received at least 1 NOAC prescription of dabigatran, rivaroxaban, or apixaban
from January 1, 2012, through December 31, 2016, with final follow-up on December 31, 2016.
EXPOSURES NOACwith orwithout concurrent use of atorvastatin; digoxin; verapamil;
diltiazem; amiodarone; fluconazole; ketoconazole, itraconazole, voriconazole, or posaconazole;
cyclosporine; erythromycin or clarithromycin; dronedarone; rifampin; or phenytoin.
MAIN OUTCOMES ANDMEASURES Major bleeding, defined as hospitalization or emergency
department visit with a primary diagnosis of intracranial hemorrhage or gastrointestinal,
urogenital, or other bleeding. Adjusted incidence rate differences between person-quarters
(exposure time for each person during each quarter of the calendar year) of NOACwith or
without concurrent medications were estimated using Poisson regression and inverse
probability of treatment weighting using the propensity score.
RESULTS Among 91 330 patients with nonvalvular atrial fibrillation (mean age, 74.7 years [SD,
10.8]; men, 55.8%; NOAC exposure: dabigatran, 45 347 patients; rivaroxaban, 54006 patients;
and apixaban, 12 886 patients), 4770major bleeding events occurred during 447037
person-quarters with NOAC prescriptions. Themost commonmedications co-prescribedwith
NOACs over all person-quarters were atorvastatin (27.6%), diltiazem (22.7%), digoxin (22.5%),
and amiodarone (21.1%). Concurrent use of amiodarone, fluconazole, rifampin, and phenytoin
with NOACs had a significant increase in adjusted incidence rates per 1000person-years of
major bleeding thanNOACs alone: 38.09 for NOAC use alone vs 52.04 for amiodarone
(difference, 13.94 [99%CI, 9.76-18.13]); 102.77 for NOAC use alone vs 241.92 for fluconazole
(difference, 138.46 [99%CI, 80.96-195.97]); 65.66 for NOAC use alone vs 103.14 for rifampin
(difference, 36.90 [99%CI, 1.59-72.22); and 56.07 for NOAC use alone vs 108.52 for phenytoin
(difference, 52.31 [99%CI, 32.18-72.44]; P < .01 for all comparisons). Comparedwith NOAC use
alone, the adjusted incidence rate formajor bleedingwas significantly lower for concurrent use
of atorvastatin, digoxin, and erythromycin or clarithromycin andwas not significantly different
for concurrent use of verapamil; diltiazem; cyclosporine; ketoconazole, itraconazole,
voriconazole, or posaconazole; and dronedarone.
CONCLUSIONS AND RELEVANCE Among patients taking NOACs for nonvalvular atrial
fibrillation, concurrent use of amiodarone, fluconazole, rifampin, and phenytoin compared
with the use of NOACs alone, was associated with increased risk of major bleeding. Physicians
prescribing NOACmedications should consider the potential risks associated with
concomitant use of other drugs.
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A trial fibrillation is a common arrhythmia with anincreasing prevalence and an association with throm-boembolism and related adverse outcomes.1 Oral
anticoagulation has been proven to prevent ischemic strokes
and prolong life for patients with atrial fibrillation.2 Non–
vitamin K oral anticoagulants (NOAC) are being used more
frequently because of their ease of administration and com-
parative efficacy compared with warfarin in reducing throm-
boembolism and major bleeding.3,4 However, for patients
with atrial fibrillation, NOACs still pose a major bleeding
risk,5 which is particularly problematic when multiple mor-
bidities, high-risk medications, polypharmacy, or drug-drug
interactions are present.6
Two large clinical trials among patients with atrial fibril-
lation were conducted from 2006 through 2009 and
approximately two-thirds of the participants (especially
the elderly) took more than 5 drugs concurrently with a
NOAC.7,8 Polypharmacy among NOAC users may increase
plasma levels and the risk of bleeding.7 Current knowledge
of drug-drug interactions associated with NOACs mainly
comes from animal studies, case reports, and limited phar-
macokinetic measurement.9,10 Particular attention has been
paid to medications (such as CYP3A4 inhibitors and
P-glycoprotein competitors) that share common metabolic
pathways with NOACs.11,12 For example, ketoconazole and
clarithromycin increase active NOAC levels in plasma and
risk of bleeding.10,13
However, complex comedications and comorbidities hin-
der the quantification of bleeding risk associated with NOAC
use in patients with atrial fibrillation.6,14 Combining NOACs
with other commonly used medications is generally avoided
in clinical trials because themedicationsmay alter NOAC lev-
els in plasma and increase the risk of bleeding. To our knowl-
edge, the influence of the concurrent use of CYP3A4 inhibi-
tors or P-glycoprotein competitors on the magnitude of
bleeding risk inNOACusershasnotbeenquantified in theclini-
cal setting.Thisstudyusedanationwidecohortofpatientswith
nonvalvular atrial fibrillation to estimate the bleeding risk in
NOAC users associated with the concurrent use of 12 com-
monly prescribed medications that share metabolic path-
ways with NOACs.
Methods
Source of Data
This retrospective cohort study obtained ethical approval
from the institutional review board of Taiwan Chang Gung
Memorial Hospital and was conducted in full compliance
with national ethical and regulatory guidelines. The institu-
tional review board determined that patient consent was not
required because all data were anonymized by the data
holder, the Taiwan National Health Insurance Administra-
tion (NHIA). The Taiwan NHI system was established in 1995
as a single-payer insurance system co-funded by the govern-
ment, employers, and beneficiaries. All citizens and foreign-
ers living in Taiwan for more than 6 months are required
by law to enroll in NHI. At the end of 2016, approximately
23 million beneficiaries were registered in NHI, which is
equivalent to a coverage rate of 99.5%.
Novel medications, such as NOACs, are often approved
and reimbursed by NHI, especially once clinical trials began
providing evidence of efficacy and safety. Since 1995, the
NHI database has recorded comprehensive registration infor-
mation and claims data, which include patient characteris-
tics, medical diagnoses, prescription details, examinations,
operations, procedures, and fees incurred. The whole data-
base is linked by the unique national personal identification,
which was anonymized before its release for research use to
prevent confidentiality leaks. The anonymized national per-
sonal identification remains consistent across the NHI data-
base and between government-held data sets, allowing valid
internal and external linkage.15 The diagnoses and proce-
dures were recorded using the International Classification of
Diseases, 9th Revision, Clinical Modification (ICD-9-CM) codes
from 1997 through 2015 and the International Classification
of Diseases, 10th Revision, Clinical Modification (ICD-10-CM)
codes since 2016.
Study Population
We identified all patients (outpatients or inpatients) with 2
consecutive records of nonvalvular atrial fibrillation diagno-
sis (ICD-9-CM code 427.31 or ICD-10-CM code I48) 15 and at
least 1 NOAC prescription (dabigatran, rivaroxaban, or
apixaban) from January 1, 2012, through December 31, 2016.
Patients with mitral stenosis or prosthetic valves were
excluded because NOACs were not indicated in this popula-
tion. Patients were followed up until death, deregistration,
or the end of the study (December 31, 2016).
Follow-up Time and Person-Quarters
In this study, each calendar year was partitioned into 4 quar-
ters for each patient and each year after the first prescription
of a NOAC. The analytic unit was 1 person-quarter.16 Person-
quarterswere used becausemedications for chronic illnesses
were refilled with a maximum length of 3 months per the
Taiwan NHI reimbursement policy. Medications and covari-
ates were assessed for each person-quarter, which simplified
the assessment of the complexprescriptionpattern ofNOACs
and multiple drugs. Person-quarters exposed to NOACs with
Key Points
Question What is the risk of major bleeding among patients with
nonvalvular atrial fibrillation treated with non–vitamin K oral
anticoagulants (NOACs) in combination with medications that
share metabolic pathways?
Findings Among 91 330 NOAC users in Taiwan, the risk of major
bleeding was significantly increased with concurrent use of
amiodarone, fluconazole, rifampin, or phenytoin compared with
NOAC use alone.
Meaning Physicians prescribing NOACmedications should
consider the potential risks associated with concomitant use of
other drugs.
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or without concurrent medications were identified. The ma-
jor bleeding risks of person-quarters exposed toNOACs and 12
concurrentmedications (atorvastatin; digoxin; verapamil; dil-
tiazem; amiodarone; fluconazole; ketoconazole, itracon-
azole, voriconazole, or posaconazole; cyclosporine; erythro-
mycin or clarithromycin; dronedarone; rifampin; and
phenytoin) were compared with person-quarters exposed to
NOAC alone. These medications were selected because they
were P-glycoprotein competitors (digoxin, verapamil, dilti-
azem, amiodarone, and cyclosporine), CYP3A4 inhibitors
(fluconazole andketoconazole, itraconazole, voriconazole, or
posaconazole), or both (atorvastatin, erythromycin or clar-
ithromycin, dronedarone, rifampin, and phenytoin), which
mayhaveapotentialdrug-drug interactionwithNOACs.11,14,17-23
Major Outcomes
The primary outcome was major bleeding, defined as a hos-
pitalization or an emergency department visit with a primary
diagnosis of intracranial hemorrhage or gastrointestinal, uro-
genital, or other bleeding, as previously described.24 People
with traumatichemorrhagewereexcluded fromanalysis.Only
1 major bleeding event was included in each person-quarter.
Secondary outcomes included site-specific bleeding. Details
of casedefinitions for theprimaryoutcomeare listed ineTable
1 in the Supplement.
Covariates
Patient demographics, comorbidities, relevant medications,
and health care utilization were identified as covariates.15,25
These covariates were assessed for each person-quarter per-
tinent to the first date of the person-quarter. Patient demo-
graphics included age, sex, and socioeconomic factors (resi-
dence, income level, andoccupation). The components of the
Charlson comorbidity index (range, 0-37; a score of 5 points
ormore has a 1-ymortality rate of 85%26),27 other comorbidi-
ties (myocardial infarction, congestive heart failure, periph-
eral vascular disease, stroke, transient ischemic attack, de-
mentia, chronic pulmonarydisease, anemia, kidneydiseases,
and hepatic diseases), components of HAS-BLED (hyperten-
sion, abnormal kidney or liver function, stroke, bleeding his-
tory, and alcohol use), number of outpatient visits, proton
pump inhibitors, aspirin, clopidogrel, ticlopidine, warfarin,
nonsteroidal anti-inflammatory drugs, glucocorticoids, insu-
lin, oral hypoglycemic agents, antihypertensives, and lipid-
lowering agentswere also assessed. The code lists of these co-
variates are shown in eTable 1 in the Supplement.
Models
Confounding by indication, which results from nonrandom
treatment allocation for concurrent medications, was an es-
sential consideration in the comparisonofmajor bleeding risk
among patients with NOAC use who were exposed vs unex-
posed to concurrent medications.28,29 The inverse probabil-
ity of treatmentweighting using the propensity scorewas ap-
plied to account for this bias.30 The propensity score was the
probability that apatientwasprescribed the concurrentmedi-
cationduringaperson-quarter. For eachperson, a specificpro-
pensity score for a specific concurrentmedicationwas calcu-
latedusing logistic regressionconsidering theaforementioned
covariatespertinent to thefirstdateof theperson-quarter.Stan-
dardized differences were estimated to assess the balance of
individual covariatesbeforeandafterpropensity scoreweight-
ing. The balance of covariates was assessed using the abso-
lute standardizedmean difference. The negligible difference
wasdefined as an absolute standardizedmeandifference less
than 0.1. eTables 2A–L in the Supplement summarize the bal-
ance of covariates between users and nonusers of each spe-
cific concurrent medication.
Statistical Analysis
Poisson regression with a generalized estimating equations
model toaccount for intra-individualcorrelationacrossperson-
quarterswasused to calculate the adjusted incidence rate dif-
ference, incidence rate ratios, and 99% CIs with consider-
ation of the inverse probability of treatment weighting using
thepropensity score. Person-quarters usingNOACalonewere
used as the reference category. Because 12 types of combina-
tionswerestudied, theregressionanalysiswasperformedsepa-
rately for each combination. In addition, a different defini-
tion of major bleeding—a hospitalization or emergency visits
due to major bleeding recorded in the primary or secondary
diagnosis—was applied as a sensitivity analysis.
Three additional analyses were conducted to ascertain
the association of a NOAC plus concurrent medications and
major bleeding: (1) The associations of a NOAC plus specific
concurrent medications with bone fractures due to vehicle
crashes (not related to the NOAC). (2) The association of the
combination of losartan (a medication to replace NOAC in
the model) plus concurrent medications with major bleed-
ing (for details, see eTable 6C and 6D in the Supplement).
(3) The association of a NOAC plus concurrent medication
groups (ie, P-glycoprotein competitors group or CYP3A4
inhibitors group) with major bleeding.
The Bonferroni method was used to consider a type I er-
rordue tomultiplecomparisons.Threesignificance levelswere
used for hypothesis tests: .05, .01, and .005. The results were
similar and the significance level of .01 was chosen to be re-
ported in themain text. Estimatesbasedon thealternative sig-
nificance levels are reported in the eTables in the Supple-
ment.Missingdatawerepresentamongpatientswithoutavalid
insurance status (estimated in<0.1%ofNOACusers), anddata
associatedwith thesepatientswereexcluded.Theentireanaly-
sis was performed using SAS (SAS Institute), version 9.4.
Results
Patient Characteristics
During2012 to2016, a total of 279734patientswithnonvalvu-
lar atrial fibrillation were identified. Among them 91 330 pa-
tients receivedNOACs.The characteristics of thepatientswith
nonvalvular atrial fibrillation at the first date of NOAC pre-
scription are listed in Table 1 and Table 2. The mean age was
74.7years (SD, 10.8), and55.8%of the studiedpopulationwere
men. The baseline average CHA2DS2-VASc (congestive heart
failure, hypertension, age ≥75 [doubled], diabetes mellitus,
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prior stroke or transient ischemic attack [doubled], vascular
disease, age65-74, female) stroke score (range0-9,maleswith
score >1may consider anticoagulation)31 was 3.9 (SD, 1.8) and
theaverageHAS-BLED(hypertension,abnormalkidneyor liver
function, stroke, bleedinghistory, and alcohol use; range0-9,
a score >3 have higher bleeding risk)32 score was 3.3 (SD, 1.3).
More than one-third of the included patients were diagnosed
withheart failureor cerebrovasculardiseaseandaquarterwith
Table 1. Characteristics and Comorbidities at Baseline Among Patients
With Nonvalvular Atrial Fibrillation Taking a NOAC
Characteristic
NOAC Users
(n = 91 330)
Age, mean (SD), ya 74.7 (10.8)
Men, No. (%) 50937 (55.8)
Residence, No. (%)
Urban 49805 (54.53)
Suburban 28667 (31.39)
Rural 12 424 (13.60)
Unknown 434 (0.48)
Occupation, No. (%)
Dependents of the insured individuals 36 750 (40.24)
Civil servants, teachers, military personnel,
and veterans
1303 (1.43)
Nonmanual workers and professionals 5065 (5.55)
Manual workers 28 240 (30.92)
Other 19972 (21.87)
Income, 2017 US $
Quintile 1
Mean 41
Median (range) 42 (0-42)
No. of Patients (%) 27893 (30.54)
Quintile 2
Mean 555
Median (range) 667 (46-730)
No. of Patients (%) 5283 (5.78)
Quintile 3
Mean 760
Median (range) 760 (760-760)
No. of Patients (%) 33213 (36.37)
Quintile 4
Mean 957
Median (range) 960 (800-1110)
No. of Patients (%) 6489 (7.11)
Quintile 5
Mean 2002
Median (range) 1607 (1160-6067)
No. of Patients (%) 18452 (20.20)
CHA2DS2-VASc score, mean (SD)b 3.9 (1.8)
HAS-BLED score, mean (SD)c,d 3.3 (1.3)
Charlson comorbidity index,
mean (SD)e
2.4 (2.5)
No. of outpatient visits
Mean 31
Median (range) 26 (0-226)
Comorbiditiesc
Cardiovascular diseases, No. (%)
Hypertension 65754 (72.00)
Myocardial infarction 3900 (4.27)
Congestive heart failure 32428 (35.51)
Percutaneous coronary intervention 2379 (2.60)
Coronary artery bypass surgery 86 (0.09)
Peripheral vascular disease 4011 (4.39)
(continued)
Table 1. Characteristics and Comorbidities at Baseline Among Patients
With Nonvalvular Atrial Fibrillation Taking a NOAC (continued)
Characteristic
NOAC Users
(n = 91 330)
Diseases of the nervous system, No. (%)
Cerebrovascular disease 30835 (33.76)
Ischemic stroke 22862 (25.03)
Transient ischemic attack 4184 (4.58)
Hemiplegia and paraplegia 4161 (4.56)
Dementia 7343 (8.04)
Metabolic disease, No. (%)
Diabetes mellitus 8163 (8.94)
Diabetes with complications 8168 (8.94)
Pulmonary disease, No. (%)
Chronic pulmonary disease 18370 (20.11)
Chronic obstructive pulmonary disease 15613 (17.10)
Chronic kidney disease, No. (%)
Not taking erythropoietin 90067 (98.62)
Kidney impairment taking erythropoietin 1251 (1.37)
End-stage kidney disease 12 (0.01)
Gastrointestinal and hepatic disease, No. (%)
Peptic ulcer disease 15364 (16.82)
Mild liver diseasef 9413 (10.31)
Moderate or severe liver diseaseg 343 (0.38)
Miscellaneous diseases, No. (%)
Any malignancy, including leukemia and lymphoma 7944 (8.70)
Metastatic tumor 749 (0.82)
HIV infection 17 (0.02)
Major bleeding history 11234 (12.30)
Anemia 4755 (5.21)
Rheumatic diseases 1057 (1.16)
Abbreviations: CHA2DS2-VASc, Congestive Heart Failure, Hypertension,
Age75 (Doubled), Diabetes Mellitus, Prior Stroke or Transient Ischemic Attack
(Doubled), Vascular Disease, Age 65-74, Female; NOAC, non–vitamin K oral
anticoagulant; HAS-BLED, hypertension, abnormal kidney or liver function,
stroke, bleeding history, and alcohol use.
a Measured at time of first appearance in sample.
b The CHA2DS2-VASc stroke score range is 0 to 9, males with a score more than 1
may consider anticoagulation.31
c Assessed during the 1 y before the first use of a NOAC.
dTheHAS-BLED score range is 0 to 9 (a score >3 indicates higher bleeding risk).32
e The Charlson comorbidity index range is 0 to 37 (the 1-y mortality rate for
a score of5 is 85%).26
f Mild liver disease included viral hepatitis, acute and subacute necrosis of liver,
and chronic liver cirrhosis.
g Moderate and severe liver disease included esophageal varices, hepatic coma,
portal hypertension, and hepatorenal syndrome.
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diabetes. Therewere45 347patients (49.7%) exposed todabi-
gatran, 54006patients (59.1%) to rivaroxaban, and 12886pa-
tients (14.1%) to apixaban during the follow-up period.
Bleeding Events
During follow-up, 4770 major bleeding events occurred dur-
ing 447 037 person-quarters with NOAC prescriptions.
Themajor bleeding events included 1177 intracranial and 3341
gastrointestinalbleedingsand182eventsoccurredinothersites.
Table3 summarizes the incidence rate, adjusted incidence rate,
and adjusted incidence rate difference for major bleeding
among the 12 combinations of a NOAC and concurrent medi-
cations. The most common medications co-prescribed with
NOACsover all person-quarterswere atorvastatin (27.6%), dil-
tiazem (22.7%), digoxin (22.5%), and amiodarone (21.1%).
The combinations of a NOAC with amiodarone, fluconazole,
rifampin, and phenytoin were associated with an increased
risk of major bleeding. Compared with person-quarters of
NOAC use alone (reference category), the adjusted incidence
rate differences per 1000 person-years of major bleeding for
aNOACcombinedwithothermedicationswere 13.94 (99%CI,
9.76-18.13) with amiodarone, 138.46 (99% CI, 80.96-195.97)
with fluconazole, 36.90(99%CI, 1.59-72.22)with rifampin,and
52.31 (99%CI, 32.18-72.44)with phenytoin. The other combi-
nationswerenot associatedwith any increase inbleeding risk.
Atorvastatin,digoxin,anderythromycinorclarithromycinwere
associated with a reduced adjusted incidence rate difference
of major bleeding (for data on the different significance lev-
els, see eTable 3 in the Supplement).
Secondary Analysis
Separate analyses for dabigatran, rivaroxaban, and apixaban
are summarized in Table 4. The patterns of bleeding risk
associated with concurrent medications of dabigatran, rivar-
oxaban, or apixaban users were similar to the primary
results. Concurrent medications of amiodarone, fluconazole,
and phenytoin with a NOAC were associated with a higher
major bleeding risk than NOAC use alone (for details, see
eTables 4A-C in the Supplement).
Major bleeding events were classified anatomically into
intracranial hemorrhage or bleeding in the gastrointestinal
tract or other sites (including urogenital, pleural, or perito-
neal bleeding). The adjusted incidence rate differences of
major bleeding associated with the combinations of a NOAC
and concurrent medications are listed in Table 5. The pat-
terns of bleeding risks were similar in these bleeding sites.
Sensitivity and Additional Analyses
In a sensitivity analysis using alternative case definitions for
major bleeding (hospitalization discharge or emergency vis-
its recorded in the primary or secondary diagnoses), the ad-
justed incidence rate differenceper 1000person-years ofma-
jor bleeding for aNOACcombinedwithothermedicationswas
31.83 (99%CI, 26.40-37.26)with amiodarone, 265.25 (99%CI,
184.72-345.78) with fluconazole, 60.21 (99% CI, 4.79-115.63)
with rifampin, and 80.10 (99% CI, 54.93-105.26) with phe-
nytoin, showing an increase in bleeding rate ratios (for de-
tails, see eTable 6A and eTable 6B in the Supplement).
The first additional analysis was to evaluate the associa-
tions between the combination of losartan and 12 concurrent
medicationsandmajorbleeding.Noneof thecombinationswas
associated with an increased bleeding risk (for details, see
eTable 6A and eTable 6C in the Supplement).
Thesecondadditionalanalysisexaminedwhether thecom-
bination of aNOACand 12 concurrentmedicationswere asso-
ciated with an unrelated adverse event, such as bone frac-
tures. None of the combination was associated with an
increased bone fracture risk (for details, see eTable 6A and
eTable 6D in the Supplement).
In the third additional analysis, 12 concurrent medica-
tions were categorized into 2 metabolic pathway groups
(P-glycoprotein competitors group (digoxin, verapamil,
diltiazem, amiodarone, and cyclosporine) and both
P-glycoprotein competitors and CYP3A4 inhibitors group
(atorvastatin; fluconazole; ketoconazole, itraconazole, vori-
conazole, or posaconazole; erythromycin or clarithromycin;
dronedarone; rifampin; andphenytoin). The combinations of
NOACwith both groups were associated with a higher bleed-
ing risk (for details, see eTable 7 in the Supplement).
Table 2. Medication Use During Follow-up Among Patients
With Nonvalvular Atrial Fibrillation Taking a NOAC
Medication
NOAC Users,
No. (%)
(n = 91 330)
Aspirin 70 228 (76.89)
Rivaroxaban 54 006 (59.13)
Nonsteroid anti-inflammatory drugs 49 886 (54.62)
Atorvastatin 48 666 (53.29)
Dabigatran 45 347 (49.65)
Diltiazem 40 934 (44.82)
Clopidogrel 38 483 (42.14)
Amiodarone 37 737 (41.32)
Antihypertensive 34 075 (37.31)
Digoxin 33 181 (36.33)
Proton pump inhibitors 29 244 (32.02)
Glucocorticoids 26 382 (28.89)
Warfarin 25 427 (27.84)
Insulin 25 313 (27.72)
Lipid-lowering agents 18 985 (20.79)
Apixaban 12 886 (14.11)
Erythromycin or clarithromycin 12 878 (14.10)
Hypoglycemic agents 11 943 (13.08)
Ticlopidine 10 233 (11.20)
Verapamil 9246 (10.12)
Dronedarone 6033 (6.61)
Phenytoin 4816 (5.27)
Ticagrelor 3902 (4.27)
Fluconazole 2477 (2.71)
Other azolesa 1174 (1.29)
Rifampin 1151 (1.26)
Cyclosporine 567 (0.62)
Abbreviation: NOAC, non–vitamin K oral anticoagulant.
a Other azoles include ketoconazole, itraconazole, voriconazole,
or posaconazole.
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Discussion
Thisnationwidepopulation-basedcohortstudypresentsthefol-
lowing main findings. First, some specific medications ad-
vised to be avoided in NOAC users,33 including diltiazem and
amiodarone, were frequently prescribed to patientswith non-
valvular atrial fibrillation in theclinical settings. Second, amio-
darone, fluconazole, rifampin, andphenytoinwere associated
with a significantly increased risk of major bleeding, whereas
some combinations not recommended by guidelineswere not
associated withmajor bleeding.
Table 3. Major Bleeding Risk Among Patients Taking a NOAC for Nonvalvular Atrial FibrillationWith ConcurrentMedications
Concurrent
Medication
Person-Quarters
With NOAC Use
No. of
Bleeding
Events
Crude Major Bleeding
Incidence Rate
(99% CI) per 1000
Person-Years
Adjusted Incidence Rate
(99% CI) per 1000
Person-Years)a
Adjusted Incidence Rate
Difference (99% CI)
per 1000 Person-Yearsa
Adjusted Rate Ratio
(99% CI)a
Atorvastatin
With 123420 1056 34.22 (31.51 to 36.94) 34.57 (31.87 to 37.50)
−14.38 (−17.76 to −10.99)b
0.71 (0.64 to 0.78)b
Withoutc 323617 3459 42.75 (40.88 to 44.63) 48.96 (46.48 to 51.57) 1 [Reference]
Digoxin
With 100513 1130 44.97 (41.52 to 48.42) 45.69 (42.23 to 49.43)
−4.46 (−8.45 to −0.47)b
0.91 (0.83 to 0.99)b
Withoutc 346524 3413 39.40 (37.66 to 41.13) 50.14 (47.34 to 53.11) 1 [Reference]
Verapamil
With 16629 236 56.77 (47.25 to 66.29) 57.26 (48.30 to 67.88)
6.35 (−3.37 to 16.07)
1.12 (0.94 to 1.34)
Withoutc 430408 4414 41.02 (39.43 to 42.61) 50.90 (48.54 to 53.38) 1 [Reference]
Diltiazem
With 101566 1300 51.20 (47.54 to 54.85) 51.91 (48.21 to 55.89)
−3.47 (−7.69 to 0.75)
0.94 (0.85 to 1.03)
Withoutc 345471 3209 37.15 (35.47 to 38.84) 55.38 (51.90 to 59.10) 1 [Reference]
Amiodarone
With 94170 1207 51.27 (47.47 to 55.07) 52.04 (48.22 to 56.15)
13.94 (9.76 to 18.13)b
1.37 (1.25 to 1.50)b
Withoutc 352867 3346 37.93 (36.24 to 39.62) 38.09 (36.19 to 40.10) 1 [Reference]
Fluconazole
With 1938 117 241.24 (183.80 to 298.70) 241.92 (192.09 to 304.66)
138.46 (80.96 to 195.97)b
2.35 (1.80 to 3.07)b
Withoutc 445099 4549 40.88 (39.32 to 42.44) 102.77 (89.76 to 117.66) 1 [Reference]
Other azolesd
With 1276 13 40.75 (11.64 to 69.87) 40.83 (20.06 to 83.12)
−40.44 (−81.56 to 0.68)
0.50 (0.24 to 1.03)
Withoutc 445761 4658 41.80 (40.22 to 43.38) 81.19 (72.27 to 91.22) 1 [Reference]
Cyclosporine
With 744 10 53.76 (9.97 to 97.56) 53.80 (24.03 to 120.46)
−24.41 (−68.26 to 19.44)
0.69 (0.30 to 1.56)
Withoutc 446293 4661 41.78 (40.20 to 43.35) 78.17 (67.72 to 90.22) 1 [Reference]
Erythromycin
or clarithromycin
With 14251 211 59.22 (48.72 to 69.72) 59.38 (49.68 to 70.98)
−39.78 (−50.59 to −28.97)b
0.60 (0.48 to 0.75)b
Withoutc 432786 4438 41.02 (39.43 to 42.60) 99.28 (87.21 to 113.01) 1 [Reference]
Dronedarone
With 15242 131 34.37 (26.64 to 42.11) 34.67 (27.53 to 43.66)
−4.20 (−12.11 to 3.72)
0.89 (0.71 to 1.13)
Withoutc 431795 4531 41.97 (40.37 to 43.58) 38.83 (37.02 to 40.73) 1 [Reference]
Rifampin
With 1405 36 102.56 (58.53 to 146.60) 103.14 (67.50 to 157.58)
36.90 (1.59 to 72.22)b
1.57 (1.02 to 2.41)b
Withoutc 445632 4632 41.58 (40.00 to 43.15) 65.66 (61.33 to 70.30) 1 [Reference]
Phenytoin
With 7158 191 106.70 (86.82 to 126.6) 108.52 (89.85 to 131.07)
52.31 (32.18 to 72.44)b
1.94 (1.59 to 2.36)b
Withoutc 439879 4458 40.54 (38.97 to 42.10) 56.07 (52.93 to 59.40) 1 [Reference]
Abbreviation: NOAC, non–vitamin K oral anticoagulant.
a Adjusted by inverse probability of treatment weighting using the propensity
score (sex, age, medical utilization, chronic kidney disease stage, anemia,
myocardial infarction, congestive heart failure, peripheral vascular disease,
cerebrovascular disease, dementia, chronic pulmonary disease, rheumatic
disease, peptic ulcer disease, mild liver disease, diabetes, hemiplegia or
paraplegia, anymalignancy, moderate or severe liver disease, metastatic solid
tumor, acquired immune deficiency syndrome, percutaneous coronary
intervention, coronary artery bypass surgery, transient ischemic attack,
hypertension, aspirin, clopidogrel, ticagrelor, ticlopidine, warfarin,
glucocorticoids, insulin, lipid-lowering agents, hypoglycemic agents,
antihypertensive, nonsteroid anti-inflammatory drugs, proton pump
inhibitors, residence, income level, and occupation).
bP < .01.
c “Without” indicates NOAC alone.
dOther azoles include ketoconazole, itraconazole, voriconazole, or
posaconazole.
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Although the 12 concurrent medications evaluated in
this study are not recommended by the updated guide-
lines,33 they are often required for NOAC users in many clini-
cal scenarios. Digoxin, diltiazem, amiodarone, and atorva-
statin were used in more than 20% of NOAC-exposed
person-quarters. This is in line with the Apixaban for Reduc-
tion in Stroke and Other Thromboembolic Events in Atrial
Fibrillation (ARISTOTLE) and the Randomized Evaluation of
Long-Term Anticoagulation Therapy (RE-LY) trials, which
reported that approximately 30% and 10% of NOAC users
were prescribed digoxin or amiodarone, respectively.34-36
On the other hand, prescription of cyclosporine and antifun-
gal azoles to NOAC users was rarely found.
There was a difference between the data from this study
andclinical trials. Inmost trials, theconcurrentmedicationsta-
tuswas reportedaspart of thebaseline characteristics andper-
centage numbers of total patients enrolled. The estimates in
this study, however, were the person-quarter exposed to a
NOAC and concurrent medications, which reflected the dy-
namic and complex prescription pattern of concurrentmedi-
cations inNOACusers inamoreprecisemanner.Toourknowl-
edge, the prevalence of rare combinations, such as antifungal
azoles or cyclosporine, with a NOAC has not been reported in
the literature.These infrequentcombinations,however,donot
necessarily carry a lower risk of major bleeding.
Amiodarone plus a NOAC was associated with signifi-
cantlymoremajor bleeding events in all primary and second-
ary analyses. During observation periods, the combination of
a NOAC and amiodarone usewas associatedwith an adjusted
incidence ratedifference formajorbleedingof 13.94eventsper
1000 person-years, which probably exceeds any benefit that
such a combination could deliver. This is, to our knowledge,
a novel observation because (1) the combination is frequent
inclinical settings, and (2) a subanalysisof theARISTOTLEtrial
showednodifference inmajor bleedingbetweenapixabanus-
ers with and without amiodarone use.36 The highest bleed-
ing risk was found in the combination of fluconazole and a
NOAC, with an adjusted incidence rate difference of 138.46
events per 1000 person-years. Therefore, fluconazole should
be avoided in NOAC users.
Paradoxically, several combinationswere associatedwith
lower bleeding risk. Atorvastatin was reported to reduce all
stoke and not to increase intracranial hemorrhage.37-39 The
lower bleeding rate associatedwith atorvastatin found in this
study might be partially related to the prevention of hemor-
rhagic transformation after ischemic stroke. Statins had been
Table 4. Major Bleeding Risk Among Patients Taking Dabigatran, Rivaroxaban, or Apixaban for Nonvalvular Atrial Fibrillation
With ConcurrentMedicationsa
Concurrent
Medication
Dabigatran Rivaroxaban Apixaban
Adjusted Incidence
Rate Difference
(99% CI)b
Adjusted Incidence
Rate Ratio
(99% CI)b
Adjusted Incidence
Rate Difference
(99% CI)b
Adjusted Incidence
Rate Ratio
(99% CI)b
Adjusted Incidence
Rate Difference
(99% CI)b
Adjusted Incidence
Rate Ratio
(99% CI)b
Atorvastatin −16.11
(−20.98 to −11.24)c
0.66
(0.56 to 0.77)c
−12.35
(−17.32 to −7.38)c
0.76
(0.66 to 0.87)c
−17.50
(−29.59 to −5.41)c
0.69
(0.51 to 0.92)c
Digoxin −5.50
(−11.14 to 0.15)
0.89
(0.76 to 1.04)
−2.06
(−7.95 to 3.82)
0.96
(0.83 to 1.11)
−6.28
(−22.32 to 9.75)
0.89
(0.65 to 1.23)
Verapamil 1.53
(−12.62 to 15.68)
1.03
(0.76 to 1.38)
9.08
(−4.71 to 22.87)
1.17
(0.90 to 1.52)
−2.74
(−36.10 to 30.62)
0.95
(0.51 to 1.77)
Diltiazem −8.13
(−16.34 to 0.08)
0.85
(0.72 to 1.01)
1.70
(−4.46 to 7.86)
1.03
(0.89 to 1.19)
3.24
(−12.58 to 19.05)
1.05
(0.79 to 1.40)
Amiodarone 13.08
(6.86 to 19.30)c
1.36
(1.17 to 1.59)c
15.41
(9.43 to 21.39)c
1.38
(1.21 to 1.58)c
12.51
(−1.43 to 26.44)
1.30
(0.98 to 1.72)
Fluconazole 148.55
(48.28 to 248.82)c
2.26
(1.44 to 3.55)c
118.10
(49.01 to 187.20)c
2.25
(1.54 to 3.30)c
226.00
(18.73 to 433.27)c
3.36
(1.69 to 6.68)c
Other azolesd −51.36
(−114.56 to 11.84)
0.48
(0.18 to 1.33)
−24.75
(−74.41 to 24.90)
0.69
(0.25 to 1.89)
NA NA
Cyclosporine −50.72
(−101.68 to 0.23)
0.40
(0.08 to 2.06)
−32.05
(−90.02 to 25.91)
0.58
(0.14 to 2.40)
196.68
(53.93 to 339.43)c
4.99
(1.43 to 17.36)c
Erythromycin
or clarithromycin
−66.04
(−81.32 to −50.76)c
0.43
(0.29 to 0.64)c
−18.19
(−36.39 to 0.41)
0.79
(0.58 to 1.06)
−65.47
(−98.61 to −32.33)c
0.41
(0.19 to 0.88)c
Dronedarone −4.96
(−20.56 to 10.63)
0.89
(0.54 to 1.45)
−3.02
(−13.02 to 6.98)
0.92
(0.68 to 1.24)
−12.74
(−32.89 to 7.40)
0.68
(0.33 to 1.41)
Rifampin 48.43
(−20.37 to 117.22)
1.76
(0.91 to 3.42)
37.51
(−24.73 to 99.75)
1.59
(0.82 to 3.09)
−33.64
(−116.35 to 49.07)
0.49
(0.04 to 6.53)
Phenytoin 54.09
(26.20 to 81.98)c
2.09
(1.53 to 2.85)c
51.84
(21.93 to 81.76)c
1.85
(1.36 to 2.51)c
54.57
(−27.5 to 136.65)
1.80
(0.90 to 3.60)
Abbreviation: NA, not applicable.
a For more details, see eTable 4 in the Supplement.
b Incidence rate difference indicates the difference in incidence rates between
person-quarters exposed to a non–vitamin K oral anticoagulant with or
without concurrent medication. Adjusted by inverse probability of treatment
weighting using the propensity score (sex, age, medical utilization, chronic
kidney disease stage, anemia, myocardial infarction, congestive heart failure,
peripheral vascular disease, cerebrovascular disease, dementia, chronic
pulmonary disease, rheumatic disease, peptic ulcer disease, mild liver disease,
diabetes, hemiplegia or paraplegia, anymalignancy, moderate or severe liver
disease, metastatic solid tumor, acquired immune deficiency syndrome,
percutaneous coronary intervention, coronary artery bypass surgery, transient
ischemic attack, hypertension, aspirin, clopidogrel, ticagrelor, ticlopidine,
warfarin, glucocorticoids, insulin, lipid-lowering agents, hypoglycemic agents,
antihypertensive, nonsteroid anti-inflammatory drugs, proton pump
inhibitors, residence, income level, and occupation).
c P value was less than .01.
dOther azoles include ketoconazole, itraconazole, voriconazole,
or posaconazole.
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suggested to decrease gastrointestinal bleeding rates in pa-
tientswith acute coronary syndromes.40 Considering the car-
diovascular benefit of atorvastatin and a lack of increased
bleeding risk, clinicians should not avoid using atorvastatin
with a NOAC in patients with nonvalvular atrial fibrillation.
The crude bleeding rate of erythromycin or clarithromycin
combined with a NOAC was higher than NOAC use alone,
but adjusted rates were higher in the NOAC use alone group.
The most plausible explanation was that clarithromycin was
an integral part of antibiotic treatment forHelicobacter pylori
infection.41 The reductionofpepticulcer bleeding riskbyanti-
Helicobacter treatment seems tooutweigh thepotential bleed-
ing risk brought by an increase in plasma concentration of the
NOACas a result of the concurrentuseofmacrolide. The lower
bleeding rate associated with digoxin was marginal. Consid-
ering the relatively unchanged plasma levels found in a phar-
macokinetic studyof dabigatran,20 digoxinplusNOACsmight
be considered a safe combination.
Many combinations were found to increase NOAC levels
inplasma in thepharmacokinetic studies,11,18-20,22butwerenot
associatedwith increased riskof bleeding in this cohort study.
For example, there were discrepancies between pharma-
cokinetic interaction and clinically relevant bleeding risk
observed in atorvastatin, digoxin, verapamil, cyclosporine,
or clarithromycinor erythromycin.On theother hand, shared
metabolic pathways might explain the high bleeding risk of
NOACsplus fluconazoleoramiodarone.Themostplausible rea-
son for this discrepancy may be that higher plasma levels of
NOAC did not necessarily result inmore bleeding, which was
also related to the comorbidity and themain drug benefits of
the concurrentmedications.Another reasonmight be that the
limited pharmacokinetic data of NOAC use was mostly col-
lected from healthy volunteers who have different pharma-
cokinetic profiles fromNOACusers,who tend tobeolder,with
more comorbidity and polypharmacy.
This is the first, toourknowledge,nationwidepopulation-
based cohort study to quantify the major bleeding risk asso-
ciated with drug-drug interaction with NOACs. The person-
quartermodelwith inverseprobabilityof treatmentweighting
using the propensity score helped to overcome confounding
by indicationbiasandthecomplexprescriptionpattern inclini-
cal setting. The design focused on a short-term risk of ad-
verse events and addressed the unstable complex prescrib-
ingbehavior.Complexprescriptiondecisionmaking for theuse
of concurrentmedications (basedonchanges inpatients’ clini-
cal conditions) was considered in the model with the prob-
ability of treatment weighting using the propensity score in
eachperson-quarter.Theobservedassociationbetweentheuse
Table 5. Site-Specific Major Bleeding Risk Among Patients Taking Non–Vitamin KOral Anticoagulants for Nonvalvular Atrial Fibrillation
With ConcurrentMedicationsa
Concurrent
Medication
Intracranial Hemorrhage Gastrointestinal Bleeding Bleeding in Other Sites
Adjusted Incidence
Rate Difference
(99% CI)b
Adjusted Incidence
Rate Ratio
(99% CI)b
Adjusted Incidence
Rate Difference
(99% CI)b
Adjusted Incidence
Rate Ratio
(99% CI)b
Adjusted Incidence
Rate Difference
(99% CI)b
Adjusted Incidence
Rate Ratio
(99% CI)b
Atorvastatin −5.37
(−7.25 to −3.49)c
0.60
(0.49 to 0.73)c
−8.83
(−11.89 to −5.77)c
0.74
(0.66 to 0.83)c
−0.28
(−1.02 to 0.45)
0.85
(0.54 to 1.35)
Digoxin 0.30
(−1.74 to 2.34)
1.02
(0.85 to 1.23)
−4.11
(−7.57 to −0.64)c
0.89
(0.79 to 0.99)c
−0.52
(−1.31 to 0.26)
0.73
(0.43 to 1.21)
Verapamil 0.42
(−4.23 to 5.08)
1.03
(0.72 to 1.47)
4.90
(−2.87 to 12.67)
1.14
(0.92 to 1.40)
1.00
(−0.79 to 2.79)
1.53
(0.70 to 3.35)
Diltiazem 1.24
(−0.92 to 3.41)
1.09
(0.91 to 1.31)
−4.18
(−7.81 to 0.01)
0.90
(0.80 to 1.01)
−0.49
(−1.31 to 0.33)
0.77
(0.46 to 1.28)
Amiodarone 8.14
(4.29 to 11.98)c
1.97
(1.67 to 2.34)c
5.64
(0.13 to 11.42)c
1.20
(1.07 to 1.34)c
0.21
(−1.17 to 1.60)
1.15
(0.73 to 1.82)
Fluconazole 44.16
(26.77 to 61.55)c
3.03
(1.82 to 5.07)c
93.65
(60.50 to 126.79)c
2.18
(1.59 to 3.00)c
1.91
(−3.61 to 7.43)
1.86
(0.28 to 12.27)
Other azolesd −14.42
(−35.18 to 6.33)
0.30
(0.05 to 1.89)
−23.84
(−58.69 to 11.02)
0.59
(0.27 to 1.30)
NA NA
Cyclosporine −8.02
(−33.90 to 17.87)
0.57
(0.09 to 3.57)
−19.51
(−64.69 to 25.66)
0.66
(0.25 to 1.76)
2.87
(−6.61 to 12.35)
2.15
(0.16 to 29.06)
Erythromycin
or clarithromycin
−12.65
(−19.41 to −5.89)c
0.48
(0.30 to 0.76)c
−29.65
(−41.41 to −17.88)c
0.59
(0.46 to 0.77)c
1.41
(−1.04 to 3.86)
1.46
(0.57 to 3.77)
Dronedarone −2.60
(−6.70 to 1.50)
0.73
(0.43 to 1.24)
−2.91
(−10.01 to 4.20)
0.89
(0.68 to 1.18)
1.03
(−0.68 to 2.74)
1.65
(0.71 to 3.86)
Rifampin 17.02
(0.51 to 33.53)c
0.48
(0.30 to 0.76)c
15.56
(−15.24 to 46.35)
1.32
(0.77 to 2.27)
4.04
(−1.60 to 9.67)
3.43
(0.54 to 21.65)
Phenytoin 50.38
(42.94 to 57.81)c
4.62
(3.52 to 6.05)c
0.92
(−11.42 to 13.26)
1.02
(0.75 to 1.38)
1.90
(−0.87 to 4.67)
1.94
(0.70 to 5.37)
Abbreviation: NA, not applicable.
a For more details, see eTable 5 in the Supplement.
b Incidence rate difference indicates the difference in incidence rates between
person-quarters exposed to a non–vitamin K oral anticoagulant with or
without concurrent medication. Adjusted by inverse probability of treatment
weighting using the propensity score (sex, age, medical utilization, chronic
kidney disease stage, anemia, myocardial infarction, congestive heart failure,
peripheral vascular disease, cerebrovascular disease, dementia, chronic
pulmonary disease, rheumatic disease, peptic ulcer disease, mild liver disease,
diabetes, hemiplegia or paraplegia, anymalignancy, moderate or severe liver
disease, metastatic solid tumor, acquired immune deficiency syndrome,
percutaneous coronary intervention, coronary artery bypass surgery, transient
ischemic attack, hypertension, aspirin, clopidogrel, ticagrelor, ticlopidine,
warfarin, glucocorticoids, insulin, lipid-lowering agents, hypoglycemic agents,
antihypertensive, nonsteroid anti-inflammatory drugs, proton pump
inhibitors, residence, income level, and occupation).
c P value was less than .01.
dOther azoles include ketoconazole, itraconazole, voriconazole,
or posaconazole.
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ofNOACs concurrentlywith specificmedications anda risk of
major bleeding was unlikely related to unmeasured bleeding
characteristics.
Severalmajorpotential applications couldbederived from
this study. First, prompt or even real-time postmarket moni-
toring is possible. Inmost standard clinical trials, it is imprac-
tical to measure the risk of a specific major adverse event re-
lated to anydrug combination.With thedesign applied in this
study, severe adverse effects of newcombinations ofmedica-
tions might be detected earlier. Second, systemic and auto-
matic monitoring of the safety profiles of new drugs with au-
tomatic data processing is possible. It is feasible to combine
a pharmacology database that contains potential drug-drug
interactionswithaclinicaldatabaseandthemethodologyused
in this study to quantify the risk of potential adverse events.
Limitations
This studyhadseveral limitations.First,becauseedoxabanwas
introduced in Taiwan after 2016, not all NOACswere studied.
Although similar interactions and patterns were found in all
other 3 NOACs, these observations may not apply to edoxa-
ban. Second, kidney and liver function data were not avail-
able in the NHI database and these factorsmay interferewith
drug-drug interaction, bleeding risk, andmedication dosing.
However, someproxy indicators (suchaserythropoietin for se-
verekidneydiseaseanddiagnosisof liverdiseases)wereadded
in themodel to represent the severity of kidneyorhepatic dis-
eases. Third, bleeding risk and anticoagulant treatment in the
Asian population have been recognized to be different from
the Western population.42 Therefore, the external generaliz-
abilityof these results, particularly toWesternpopulationmay
be limited. Fourth, dosages of NOACs and the studied medi-
cationswerenotconsidered inthemodelbecause itwouldhave
complicated the complex model further.
Conclusions
Among patients taking NOACs for nonvalvular atrial fibrilla-
tion, concurrentuseofamiodarone, fluconazole, rifampin, and
phenytoin compared with the use of NOACs alone, was asso-
ciated with increased risk of major bleeding. Physicians pre-
scribingNOACmedications shouldconsider thepotential risks
associated with concomitant use of other drugs.
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